Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 29, 2019

Merck to invest €150m in Swiss biologics production site

German healthcare company Merck has revealed plans to invest €150m to expand the capacity of its Swiss biotech medicines manufacturing site in Aubonne.

German healthcare company Merck has revealed plans to invest €150m to expand the capacity of its Swiss biotech medicines manufacturing site in Aubonne.

Over the 2019-2023 period, this investment will be used for a new building that will produce biologics to be supplied for more than 150 countries in order to cater to increasing demand.

Among other medicines, the production capacity is being boosted for fertility treatment Gonal-f, oncology drug Bavencio and products in clinical development such as M7824 (bintrafusp alfa), a cancer candidate.

Merck Healthcare CEO Belén Garijo said: “This investment reflects our commitment to ensuring that our medicines always meet the highest quality standards and are readily available to patients all over the world whenever they need them.

“It is an expression of our confidence in the future growth of our Healthcare business sector.”

The new building will include the latest technologies for aseptic filling and quality control. Merck is also planning for a design and flexible operations model that will allow an increase in capacity.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“The new building is expected to be completed by next year, with operations in the new quality control labs scheduled to be commenced in 2021.”

In addition, the aseptic filling lines will be fitted with isolator technology to ensure the safety of injectable drugs. The company will build two lines for freeze-dried formulations and liquid formulations, respectively.

Existing infrastructure will be replaced with these lines and new quality control labs. Technological upgrades and increased capacity is estimated to enable the production of up to 27 million vials annually.

The new building is expected to be completed by next year, with operations in the new quality control labs scheduled to be commenced in 2021.

The aseptic filling lines are set to become operational in 2023.

This latest expansion brings Merck’s total investment in Switzerland over the last decade to €800m. The company employs a total of 2,300 people across 11 locations in the country.

Earlier this month, Merck revealed plans to invest €1bn over the next five years in the site at its global headquarters Darmstadt, Germany.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU